# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Jefferies analyst Akash Tewari maintains Eli Lilly and Co (NYSE:LLY) with a Buy and raises the price target from $925 to $957.
Judge Karen Marston takes over the high-profile Ozempic litigation involving over 10,000 lawsuits. Here's the latest.
May labor market report: strong job gains and wage growth, reduces chances of rate cut. Interest-rate sensitive sectors underpe...
New ETFs focusing on weight-loss drugs have launched. However, industry observers caution about their long-term prospects and t...
Companies from food and beverage to fitness are adapting to the increased demand for these drugs, hoping to capitalize on shift...
The FDA's advisory committee will review Eli Lilly's Phase 3 study on donanemab for Alzheimer's disease on June 10....
- Reuters